Literature DB >> 22483860

Tooth extraction in patients on zoledronic acid therapy.

Marco Mozzati1, Valentina Arata, Giorgia Gallesio.   

Abstract

OBJECTIVES: Surgical management of patients following zoledronic acid therapy is particularly difficult, since the dental extraction is the main cause of BRONJ.
METHODS: A case-control study was conducted on 176 patients treated with intravenous (IV) bisphosphonates for oncologic pathologies who also underwent dental extractions. The study was divided randomly into two groups: 91 were treated with Plasma Rich in Growth Factor Plasma (PRGF) (study group) and the other 85 were not treated with the growth factor preparation (control group).
RESULTS: Panoramic X-ray and computed tomography were performed both before and 60 months after surgery. By clinical and radiological diagnosis, BRONJ was diagnosed in only 5 patients in the control group at an average of 91, 6 days after tooth extraction.
CONCLUSIONS: We hypothesize that Plasma Rich in Growth Factor (PRGF) is important for the successful treatment of patients on bisphosphonates to restore the osteoblast/osteoclast homeostatic cycles via autologous cytokines. Moreover, this protocol reduces the risk of BRONJ when it is necessary to perform dental extractions in patients undergoing IV bisphosphonate treatment.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22483860     DOI: 10.1016/j.oraloncology.2012.03.009

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  21 in total

1.  Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.

Authors:  T Hasegawa; S Hayashida; E Kondo; Y Takeda; H Miyamoto; Y Kawaoka; N Ueda; E Iwata; H Nakahara; M Kobayashi; S Soutome; S I Yamada; I Tojyo; Y Kojima; M Umeda; S Fujita; H Kurita; Y Shibuya; T Kirita; T Komori
Journal:  Osteoporos Int       Date:  2018-11-07       Impact factor: 4.507

2.  Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.

Authors:  Akihiko Matsumoto; Masanori Sasaki; Rainer Schmelzeisen; Yukiko Oyama; Yoshihide Mori; Pit Jacob Voss
Journal:  Clin Oral Investig       Date:  2016-02-29       Impact factor: 3.573

3.  Clinical, radiographical, and histological outcomes of plasma rich in growth factors in extraction socket: a randomized controlled clinical trial.

Authors:  Eduardo Anitua; Alia Murias-Freijo; Mohammad Hamdan Alkhraisat; Gorka Orive
Journal:  Clin Oral Investig       Date:  2014-07-08       Impact factor: 3.573

4.  Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study.

Authors:  Takuya Asaka; Noritaka Ohga; Yutaka Yamazaki; Jun Sato; Chiharu Satoh; Yoshimasa Kitagawa
Journal:  Clin Oral Investig       Date:  2016-11-11       Impact factor: 3.573

5.  The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.

Authors:  Meltem Ozden Yüce; Emine Adalı; Gözde Işık
Journal:  Clin Oral Investig       Date:  2021-01-03       Impact factor: 3.573

6.  PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells.

Authors:  Eduardo Anitua; Mar Zalduendo; María Troya; Gorka Orive
Journal:  Clin Oral Investig       Date:  2015-07-23       Impact factor: 3.573

7.  Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution's experience.

Authors:  Onur Şahin; Birkan Tatar; Ceren Ekmekcioğlu; Toghrul Aliyev; Onur Odabaşı
Journal:  J Clin Exp Dent       Date:  2020-08-01

Review 8.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk; Jens-Uwe Peter
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

Review 9.  New cancer therapies and jaw necrosis.

Authors:  V Patel; M Kelleher; C Sproat; J Kwok; M McGurk
Journal:  Br Dent J       Date:  2015-09-11       Impact factor: 1.626

Review 10.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.